Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | F2RL1 | P55085 | 8/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | TXN | P10599 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11687199 | 1.00 | GPR84 (0.46) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL78832 | 1.00 | GPR84 (0.46) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL80111 | 1.00 | GPR84 (0.46) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL3444257 | 1.00 | GPR84 (0.46) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL1136687 | 1.00 | GPR84 (0.46) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| Bromide SCHEMBL28418264 | 0.98 | GPR84 (0.44) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL5610773 | 0.98 | GPR84 (0.43) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL11627014 | 0.93 | CYP1A2 (0.42) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL18125130 | 0.93 | CYP1A2 (0.42) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 | |
| Nitric Acid SCHEMBL29012412 | 0.87 | GPR84 (0.42) | GPR84CYP1A2CYP3A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1920773-A1 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2008-05-14 | — | — | EP | claimed |
| EP-0963200-B9 | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS COMPRISING THALODOMIDE AND A NSAID | CHILDRENS MEDICAL CENTER (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1586322-A2 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2005-10-19 | — | — | EP | claimed |
| EP-0963200-B1 | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS COMPRISING THALODOMIDE AND A NSAID | CHILDRENS MEDICAL CENTER (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2004-12-09 | — | — | US | claimed |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2003-10-09 | — | — | US | claimed |
| JP-2002513391-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-0963200-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | The Children's Medical Center Corporation (US) | 1999-12-15 | — | — | EP | claimed |
| WO-1998019649-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-14 | — | — | WO | claimed |
| US-20250163172-A1 | Combination Treatment for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-22 | — | — | US | disclosed |
| US-20250122297-A1 | Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12234293-B2 | Treatment for primary amyloidosis with anti-BCMA binding protein | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| US-12227585-B2 | Anti-BCMA antibody drug conjugate combination treatment for cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| US-20240009307-A1 | Combination Treatment for Cancer | GlaxoSmithKline Intellectual Property Developement Limited (GB) | 2024-01-11 | — | — | US | disclosed |
| EP-1586322-A2 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-0963200-B1 | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS COMPRISING THALODOMIDE AND A NSAID | CHILDRENS MEDICAL CENTER (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2004-12-09 | — | — | US | disclosed |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2003-10-09 | — | — | US | disclosed |
| EP-0963200-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | The Children's Medical Center Corporation (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998019649-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227585-B2 | Anti-BCMA antibody drug conjugate combination treatment for cancer | CD79B, CD22, CD40 | GPR84 2226/4885CYP1A2 4466/4885CYP3A4 2948/4885 |
| US-20250122297-A1 | Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer | CD79B, CD22, CD40 | GPR84 2226/4885CYP1A2 4466/4885CYP3A4 2948/4885 |
| US-20240009307-A1 | Combination Treatment for Cancer | BCL6, SERPINA6, CD79B | GPR84 2150/4885CYP1A2 4850/4885CYP3A4 4247/4885 |
| US-20250163172-A1 | Combination Treatment for Cancer | SERPINA6, BCL6, BCOR | GPR84 2131/4885CYP1A2 4865/4885CYP3A4 4606/4885 |
| US-12234293-B2 | Treatment for primary amyloidosis with anti-BCMA binding protein | SERPINA6, BCL6, HSPBP1 | GPR84 2943/4885CYP1A2 4744/4885CYP3A4 4624/4885 |
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | PGF, PTGS1, PTGIS | GPR84 2710/4885CYP1A2 658/4885CYP3A4 716/4885 |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | PGF, PTGS1, PTGIS | GPR84 2710/4885CYP1A2 658/4885CYP3A4 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.